Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that separates sperm from semen sample using electrophoresis and specialist membranes for the use in fertility treatments, including IVF for humans, as well as for artificial reproductive techniques for animals; and a polymer membrane separation technology using polyacrylamide hydrogel membranes with electrophoresis. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited is headquartered in Homebush, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 2 8415 7300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Memphasys (ASX:MEM) Frequently Asked Questions
What is Memphasys' stock symbol?
Memphasys trades on the ASX under the ticker symbol "MEM."
Has Memphasys been receiving favorable news coverage?
News articles about MEM stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Memphasys earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Memphasys.
Who are some of Memphasys' key competitors?
Some companies that are related to Memphasys include Matinas BioPharma (MTNB), Sirona Biochem (SBM), Immutep (IMM), Medlab Clinical (MDC), OncoCyte (OCX), OncoCyte (OCX), Oxford Biodynamics (OBD), Helix Biopharma (HBP), IntelGenx Technologies (IGX), Imugene (IMU), 4d Pharma (DDDD), Orthocell (OCC), Pediapharm (PDP), Circassia Pharmaceuticals (CIR) and Equillium (EQ).
Who are Memphasys' key executives?
Memphasys' management team includes the folowing people:
- Ms. Alison Mary Coutts B.E. (Chem), GDipBiotech, MBA, Exec. Chairman & Interim CEO
- Pablo Neyertz, Director of Fin.
- Mr. Malcolm Coleman, Chief Financial Officer of Nusep Ltd
- Mr. Andrew Metcalfe, Company Sec.
How big of a company is Memphasys?
What is Memphasys' official website?
How can I contact Memphasys?
The company can be reached via phone at 61 2 8415 7300.
MarketBeat Community Rating for Memphasys (ASX MEM)
MarketBeat's community ratings are surveys of what our community members think about Memphasys and other stocks. Vote "Outperform" if you believe MEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
